cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma
Centre Jean Perrin
59 participants
Oct 13, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment
Eligibility
Inclusion Criteria4
- Selection Criteria:
- Patient included in NeckTAR study
- Written informed consent signed for NeckTAR-IN study
- Affiliation to the French social security system
Interventions
The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07178847